Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 11 Obesity 4 Sarcopenia 3 Polycystic Ovary Syndrome 3 Neoplasms 3 Melanoma 3 Prostatic Neoplasms 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Malnutrition 2 Lymphoma, Follicular 2 Colorectal Neoplasms 2 Breast Carcinoma In Situ 2 Wound Infection 1 Weight Loss 1 Urinary Bladder Neoplasms 1 Surgical Wound Infection 1 Stomach Neoplasms 1 Smoldering Multiple Myeloma 1 Skin Neoplasms 1 Psoriasis 1 Precancerous Conditions 1 Postoperative Complications 1 Polyps 1 Phagocyte Bactericidal Dysfunction 1 Pain 1 Paget's Disease, Mammary 1 Overweight 1 Osteoarthritis 1 Olfaction Disorders 1 Non-alcoholic Fatty Liver Disease 1

Interventions

Carboplatin 340 Cisplatin 238 Paclitaxel 203 Radiotherapy 195 Pemetrexed 187 Docetaxel 169 Gemcitabine 157 pembrolizumab 141 Erlotinib Hydrochloride 107 Etoposide 99 Magnetic Resonance Spectroscopy 93 Bevacizumab 91 Specimen Handling 76 Nivolumab 73 Radiosurgery 72 durvalumab 69 Vinorelbine 54 osimertinib 53 Gefitinib 49 Drug Therapy 49 atezolizumab 42 Irinotecan 42 Radiation 40 Topotecan 39 Biopsy 39 Standard of Care 38 Cyclophosphamide 38 Cetuximab 35 Blood Specimen Collection 33 Taxes 32

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lung Neoplasms × Docosahexaenoic Acids × Clear all

NCT03936621 2019-05-07

Omega

British Columbia Cancer Agency

Phase 2 Unknown

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡